Belzutifan — Drug Intelligence | 15 EU Trials

Filter these 15 trials by condition, phase, country and more.

Open in Search →

15 Registered trials

6 Recruiting

8 Completed trials

3 Sponsors

19 Countries

Phase III

Phase II

Phase I/II

Phase III: 6 Phase II: 4 Phase I/II: 5

Oversight events:

1 serious breach 14 temporary halts 1 urgent safety measure across 3 trials

View oversight register →

Indications tested

Renal cell carcinoma 6 Bile duct cancer 1 Endometrial cancer 1 Ductal adenocarcinoma of pancreas 1 Colorectal cancer 1 Von Hippel-Lindau disease 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 13 Peloton Therapeutics Inc. 1 Vall D Hebron Institute Of Oncology 1

All trials

15 total

Moonlanding: A phase 2 study of pembrolizumab plus belzutifan, with or without lenvatinib, given before the main treatment for localized kid… Pending

2024-519673-18-00 Phase II 1 country Vall D Hebron Institute Of Oncology
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043) Recruiting

2025-524160-38-00 Phase III 10 countries Merck Sharp & Dohme LLC
A clinical study of different treatments for kidney cancer (MK-3475-03A) Recruiting

2023-506838-68-00 Phase I/II 5 countries Merck Sharp & Dohme LLC
A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-034) Recruiting

2024-516993-31-00 Phase III 9 countries Merck Sharp & Dohme LLC
A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting

2024-517136-21-00 Phase III 12 countries Merck Sharp & Dohme LLC
A clinical study of combination therapies in people with kidney cancer (MK-3475-03C) Recruiting

2024-516437-12-00 Phase I/II 3 countries Merck Sharp & Dohme LLC
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting

2023-506987-15-00 Phase I/II 11 countries Merck Sharp & Dohme LLC
Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended

2023-505023-31-00 Phase III 14 countries Merck Sharp & Dohme LLC
Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors Ended

2023-503905-12-00 Phase II 4 countries Merck Sharp & Dohme LLC
An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended

2022-502122-41-00 Phase III 14 countries Merck Sharp & Dohme LLC
Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended

2024-510620-39-00 Phase III 13 countries Merck Sharp & Dohme LLC
A clinical study of different treatments for kidney cancer (MK-3475-03B) Ended

2023-506839-15-00 Phase I/II 5 countries Merck Sharp & Dohme LLC
A clinical study of belzutifan for treatment of kidney cancer (MK-6482-013) Ended

2022-502123-21-00 Phase II 4 countries Merck Sharp & Dohme LLC
An Open-Label Phase 2 study to evaluate the effect of PT2977 for the treatment of von Hippel-Lindau Disease-Associated with kidney cancer Ended

2023-509119-99-00 Phase II 2 countries Peloton Therapeutics Inc.
Phase 1/2 Study of Belzutifan Plus Palbociclib Versus Belzutifan in Advanced Renal Cell Carcinoma (RCC) Ended

2023-504963-17-00 Phase I/II 6 countries Merck Sharp & Dohme LLC

Showing 1–15 of 15 trials

← All drugs A–Z